How to Evaluate a Custom Peptide Synthesis Quote

The cheapest custom peptide synthesis quote is often not the lowest-cost proposal. One supplier may quote crude synthesis yield, another may promise purified delivered mass, and a third may include analytical work that the others price separately.

To compare quotes, send every supplier the same written specification and normalize five things: technical scope, delivered quantity, purity definition, analytical package, and failure terms. The quote should state what will be delivered and how acceptance will be demonstrated.

The Short Quote Checklist

Every request for quotation should specify:

Sequence, termini, disulfide pattern, modifications, isotope labels, conjugates, and required salt or counter-ion form.
Intended use: discovery research, assay reagent, preclinical material, analytical standard, clinical API, or commercial API.
Required delivered quantity and whether that means gross lyophilized mass or net peptide content.
Purity target, analytical method, acceptance criteria, and whether the result excludes water and counter-ions.
Required identity, purity, content, residual solvent, counter-ion, water, bioburden, endotoxin, or other tests.
Packaging, storage, shipping conditions, documentation, delivery date, and resynthesis or refund terms.

How SPPS Works

In solid-phase peptide synthesis (SPPS), the first protected amino acid is attached to a solid support. The chain is extended through repeated deprotection, washing, activation, and coupling cycles. After assembly, the peptide is cleaved from the support, side-chain protecting groups are removed, and the crude material is purified and isolated.

Incomplete coupling, deletion sequences, side reactions, aggregation on the resin, and damage during cleavage can reduce crude quality and recovery. A technically credible quote should reflect sequence-specific risks rather than pricing amino-acid count alone.

Fmoc or Boc?

Fmoc and Boc are orthogonal protecting-group strategies with different deprotection and cleavage conditions. Fmoc-based SPPS is widely used, while Boc chemistry remains useful for selected sequences and process strategies. The appropriate route depends on the sequence, protecting groups, modifications, scale, equipment, impurity risks, and the supplier's validated experience.

A buyer usually should define the required product rather than prescribe a synthesis route. For difficult or regulated projects, ask the supplier to explain the proposed chemistry, known sequence liabilities, expected impurity classes, and contingency plan.

Purification and QC

Preparative chromatography is commonly used to separate the target from deletion, insertion, oxidation, epimerization, and other process-related species. The supplier should choose a purification method suitable for the peptide's hydrophobicity, charge, solubility, and impurity profile.

Intact-mass spectrometry and analytical chromatography answer different questions: observed mass supports identity, while the chromatographic method estimates relative purity under its stated conditions. Complex sequences or regulated programs may require orthogonal methods, peptide mapping, disulfide assignment, or additional structural characterization.

There Is No Universal Purity Grade

Labels such as “crude,” “standard,” “research grade,” and “GMP grade” are not interchangeable technical specifications. Define a numerical acceptance criterion, the method used to measure it, the treatment of closely related impurities, and any application-specific tests. Clinical suitability cannot be inferred from a headline HPLC percentage.

Higher chromatographic purity can require additional purification and reduce recovered yield, but the cost impact depends on the sequence and process. Request options only when each option includes the same quantity basis and analytical definition.

What Drives the Price

Length and route. Longer sequences require more coupling cycles and can accumulate deletion products, but amino-acid count alone does not predict feasibility. Fragment condensation, ligation, hybrid, or recombinant approaches may be considered depending on the molecule and scale.

Sequence difficulty. Hydrophobicity, aggregation, steric hindrance, oxidation-prone residues, aspartimide formation, racemization risk, and disulfide topology can affect route development, crude quality, and purification recovery.

Modifications. Terminal modifications, isotope labels, phosphorylation, cyclization, fluorescent tags, lipidation, PEGylation, conjugation, and counter-ion exchange can add material, process-development, purification, or analytical requirements.

Scale. Larger quantities may reduce unit cost after a process is established, but scale-up can require route changes, additional development, equipment time, or a different purification strategy.

Purity. A higher purity specification can require additional purification and reduce recovered yield, but the cost impact depends on the sequence, process, scale, and analytical requirements. Compare quotes only when their purity methods and quantity basis are equivalent.

Lead Times

A credible timeline separates feasibility review, synthesis, purification, testing, quality review, and shipment. Longer sequences, difficult synthesis, multiple modifications, high purity, method development, or larger scale can extend any of those stages. Ask whether the quoted date is an estimated synthesis completion date or a committed shipment date after quality release.

Normalize the Deliverables Before Comparing Price

Quote item	What the proposal should state	Why it matters
Quantity	Purified delivered mass and, when relevant, net peptide content	Gross lyophilized mass can include water, counter-ions, salts, and excipients.
Purity	Method, wavelength, column, integration rules, specification, and result	A percentage without the method is not comparable across suppliers.
Identity	Expected and observed mass, instrument or method, and acceptance rule	Chromatographic purity does not establish that the main peak is the requested peptide.
Impurities	Reporting thresholds and treatment of deletion, insertion, oxidation, and epimerization products	Two materials with the same headline purity can have different impurity profiles.
Counter-ion and water	Requested form, test method, and result or limit	These affect molecular-weight calculations and actual peptide content.
Documentation	COA, chromatograms, spectra, batch record summary, methods, and stability data	The documentation package should match the intended use.
Failure terms	Acceptance window, deviation handling, resynthesis, partial delivery, and refund policy	Difficult sequences can fail or deliver below the requested yield.

Purity Is Not Peptide Content

Analytical HPLC generally reports the relative area of detected components under one method. It does not, by itself, determine how much of the vial is the target peptide by weight. Water, residual solvents, counter-ions, and non-UV-absorbing material can contribute to gross mass without appearing as peptide-related HPLC peaks.

If concentration or stoichiometry matters, request a content assay appropriate to the material, together with water and counter-ion results. Ask suppliers to state whether the ordered quantity is based on gross weight or corrected peptide content. This distinction should be resolved before purchase, not after material arrives.

Match the Analytical Package to the Risk

Discovery material. Intact-mass confirmation and a documented chromatographic purity method may be sufficient for many early research uses. Add content, solubility, or functional testing when the experiment depends on accurate concentration or activity.

Complex or modified peptides. Consider peptide mapping, amino acid analysis, counter-ion testing, water determination, disulfide assignment, or orthogonal chromatography where intact mass and one HPLC method cannot resolve the relevant risks.

Regulated API programs. The proposal should address process and impurity understanding, validated or qualified methods as appropriate to phase, residual solvents, elemental impurities where relevant, stability, traceability, change control, deviations, and quality-unit release. The EMA synthetic peptide guideline specifically addresses manufacturing, characterization, specifications, analytical control, conjugation, and peptide-related impurities. ICH Q7 and Q11 provide the broader API quality and process-development framework.

Confirm Who Performs the Work

Ask for the legal manufacturer, manufacturing site, testing site, and any subcontracted purification or analytical work. A sales office, broker, or catalog vendor is not automatically the original manufacturer. For API work, the COA and supply-chain documentation should identify the original manufacturer and the batch being released.

GMP is site- and activity-specific. Do not treat a company-level GMP badge as proof that the quoted peptide, process, building, or testing activity falls within the inspected scope. Request the certificate or inspection evidence, facility address, scope, issuing authority, and current status.

Use a Weighted Scorecard

A practical comparison gives commercial price only 10% of the first-pass score:

30% technical fit: relevant sequence, modification, scale, purification, and troubleshooting experience.
25% quality and documentation: methods, traceability, quality oversight, facility evidence, and change control.
20% defined deliverables: quantity basis, specifications, raw data, packaging, and acceptance criteria.
15% execution plan: realistic milestones, named responsibilities, communication, and deviation handling.
10% commercial terms: total price, payment milestones, shipping, taxes, and failure allocation.

Change the weights to match the program, but score every supplier against the same requirements. A lower initial price should not offset an undefined analytical package or an unusable quantity basis.

Red Flags in a Synthesis Proposal

The supplier accepts a difficult sequence immediately without a feasibility review or technical questions.
The quote says only “95% purity” without a method, acceptance rule, chromatogram, or identity test.
Quantity is described as yield without saying crude, purified, gross mass, or net peptide content.
The proposal claims GMP but does not identify the manufacturing site and applicable scope.
Subcontracted manufacturing or testing is undisclosed.
Failure, partial delivery, deviation, and resynthesis terms are absent.
The supplier will not provide a representative COA or explain what batch-specific raw data accompanies delivery.

Choose the Supplier Model That Fits the Program

Catalog and research synthesis providers can be appropriate for straightforward discovery quantities with standardized specifications and analytical packages.

Specialist synthesis companies are better candidates when the sequence requires unusual modifications, difficult purification, conjugation, or method development.

Clinical and commercial CDMOs should be evaluated for process development, scale-up, GMP manufacturing, stability, quality agreements, change control, and regulatory documentation. A provider that is cost-effective for milligram research material may not be the right organization for a clinical API program.

Ask before ordering: What exactly counts as delivered quantity? Which tests and raw data are included? Who performs synthesis, purification, and release testing? What happens if the peptide misses quantity, purity, identity, solubility, or delivery requirements?

Use the custom peptide synthesis company directory to build a shortlist, then send the same specification to every provider. For clinical or commercial API programs, also compare the peptide CDMO directory and verify facility-specific quality evidence directly.